Why 2 drug royalty deals worth close to $2 billion could signal the future


Companies with interests in approved drugs or late-stage drugs can draw cash immediately by selling their sales-based royalty streams.

Previous Why Oregon biotech is finally coming into its own
Next An Oregon sector that, quietly, generates billions